Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized Sargramostim + Nivolumab in Metastatic Melanoma
NCT05717140Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sargramostim in melanoma, sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose, Incidence of Adverse Events and 2 more. Planned start Oct 2025; status: withdrawn.
02
Drugs
sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05717140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717140.